413 related articles for article (PubMed ID: 28756335)
21. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
22. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.
Joshi A; Dimino T; Vohra Y; Cui C; Yan GX
J Electrocardiol; 2004; 37 Suppl():7-14. PubMed ID: 15534787
[TBL] [Abstract][Full Text] [Related]
23. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
24. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
27. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
28. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
Vicente J; Stockbridge N; Strauss DG
J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
[TBL] [Abstract][Full Text] [Related]
29. Oscillations of cardiac wave length and proarrhythmia.
Hondeghem LM; Dumotier B; Traebert M
Naunyn Schmiedebergs Arch Pharmacol; 2010 Oct; 382(4):367-76. PubMed ID: 20803191
[TBL] [Abstract][Full Text] [Related]
30. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
[TBL] [Abstract][Full Text] [Related]
31. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study.
Viswanathan PC; Rudy Y
Cardiovasc Res; 1999 May; 42(2):530-42. PubMed ID: 10533588
[TBL] [Abstract][Full Text] [Related]
32. Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.
Obejero-Paz CA; Bruening-Wright A; Kramer J; Hawryluk P; Tatalovic M; Dittrich HC; Brown AM
Sci Rep; 2015 Nov; 5():17623. PubMed ID: 26616666
[TBL] [Abstract][Full Text] [Related]
33. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
34. Cellular mechanisms of Torsade de Pointes.
Poelzing S; Rosenbaum DS
Novartis Found Symp; 2005; 266():204-17; discussion 217-24. PubMed ID: 16050270
[TBL] [Abstract][Full Text] [Related]
35. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.
Wu L; Guo D; Li H; Hackett J; Yan GX; Jiao Z; Antzelevitch C; Shryock JC; Belardinelli L
Heart Rhythm; 2008 Dec; 5(12):1726-34. PubMed ID: 19084812
[TBL] [Abstract][Full Text] [Related]
36. A 2015 focus on preventing drug-induced arrhythmias.
Bossu A; van der Heyden MA; de Boer TP; Vos MA
Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
[TBL] [Abstract][Full Text] [Related]
37. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Cubeddu LX
Curr Cardiol Rev; 2016; 12(2):141-54. PubMed ID: 26926294
[TBL] [Abstract][Full Text] [Related]
38. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
39. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
40. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
